On Wednesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Idera Pharmaceuticals, (NASDAQ:IDRA), Mast Therapeutics, (NYSEMKT:MSTX), Axion Power International, (NASDAQ:AXPW), Yodlee, (NASDAQ:YDLE)
Idera Pharmaceuticals, (NASDAQ:IDRA), with shares declined -5.12%, closed at $3.52.
Mast Therapeutics, (NYSEMKT:MSTX), with shares dropped -5.05%, settled at $0.46.
Axion Power International, (NASDAQ:AXPW), with shares dipped -8%, and closed at $0.0368.
Yodlee, (NASDAQ:YDLE), plummeted -4.98%, and closed at $12.79.
Latest NEWS regarding these Stocks are depicted underneath:
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. (IDRA), declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL).
Idera is presently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation (ClinicalTrials.gov identifier NCT02252146). Preclinical studies have shown that in B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, counting DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling.
The objectives of the trial are to evaluate the compound’s safety, tolerability and clinical activity. The protocol comprises three dose-escalation cohorts of IMO-8400 administered subcutaneously.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
Mast Therapeutics, Inc. (NYSEMKT:MSTX)
Mast Therapeutics, Inc. (MSTX), stated financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter 2014 Operating Results:
- The Corporation’s net loss for the fourth quarter of 2014 was $7.3 million, or $0.05 per share (basic and diluted), contrast to a net loss of $5.7 million, or $0.06 per share (basic and diluted), for the same period in 2013.
- Research and development (R&D) expenses for the fourth quarter of 2014 were $4.9 million, an raise of $1.4 million, or 40%, contrast to $3.5 million for the same period in 2013. The raise was due mainly to raises of $0.9 million in external clinical study fees and expenses related primarily to raised enrollment in EPIC, the Corporation’s Phase 3 study of vepoloxamer in sickle cell disease, and $0.5 million in nonclinical study fees and expenses related primarily to research-related manufacturing costs for vepoloxamer.
- Selling, general and administrative (SG&A) expenses for the fourth quarter of 2014 were $2.4 million, an raise of $0.3 million, or 12%, contrast to $2.1 million for the same period in 2013. The raise resulted primarily from an raise in fees for accounting, tax and legal services and personnel costs.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical corporation, develops therapies for serious or life-threatening diseases. The corporation’s lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure.
Axion Power International Inc. (NASDAQ:AXPW)
Axion Power International Inc. (AXPW), stock volatility for the week is 45.51%, while for the month remained 36.98%.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -4.26diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -21.80% and Annual EPS growth for the past 5 years is considered as 27.40%.
Axion Power International, Inc. is engaged in the design, development, manufacture, and sale of advanced energy storage devices, components, and systems based on its patented PbC Technology. Its PbC batteries and components are used in energy system storage functions. The corporation also manufactures standard and specialty lead-acid batteries. Axion Power International, Inc. was founded in 2003 and is based in New Castle, Pennsylvania.
Yodlee, Inc. (NASDAQ:YDLE)
Yodlee, Inc. (YDLE), declared the launch of the Yodlee Business Cash Flow with Forecasting FinApp, which has been named Most Innovative Industry Partner for the 2015 Monarch Innovation Awards hosted by Barlow Research Associates.
Yodlee’s new Business Cash Flow with Forecasting FinApp provides businesses from around the world a solution that delivers a complete picture of their cash flow recently, and a forecast for the forthcoming three months.
The forecasting function allows users to understand where they may have a funding short-fall, or excess cash on hand, and take appropriate action (e.g. apply for a loan, or move money to a timed deposit account).
Yodlee, Inc. operates a technology and applications platform that provides digital financial services in the cloud. The corporation’s platform, the Yodlee Financial Cloud, delivers a range of financial applications (FinApps) for the retail financial, wealth administration, small business, card, and other financial solutions sectors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
